Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VIR |
---|---|---|
09:32 ET | 16314 | 10.495 |
09:34 ET | 2295 | 10.51 |
09:36 ET | 2651 | 10.75 |
09:38 ET | 1350 | 10.77 |
09:39 ET | 12480 | 10.88 |
09:41 ET | 12467 | 10.88 |
09:43 ET | 100 | 10.85 |
09:45 ET | 2256 | 10.91 |
09:48 ET | 1246 | 10.84 |
09:50 ET | 4429 | 10.84 |
09:52 ET | 680 | 10.82 |
09:54 ET | 3835 | 10.81 |
09:56 ET | 3448 | 10.83 |
09:57 ET | 1516 | 10.85 |
09:59 ET | 3979 | 10.86 |
10:01 ET | 1775 | 10.87 |
10:03 ET | 1000 | 10.87 |
10:06 ET | 3600 | 10.895 |
10:08 ET | 1253 | 10.93 |
10:10 ET | 5062 | 10.935 |
10:12 ET | 4477 | 10.93 |
10:14 ET | 1759 | 10.97 |
10:15 ET | 1590 | 11 |
10:17 ET | 4008 | 10.95 |
10:19 ET | 3084 | 10.928 |
10:21 ET | 900 | 10.89 |
10:24 ET | 1900 | 10.96 |
10:26 ET | 2262 | 10.94 |
10:28 ET | 700 | 10.95 |
10:30 ET | 3007 | 10.89 |
10:32 ET | 1948 | 10.8782 |
10:33 ET | 2780 | 10.92 |
10:35 ET | 999 | 10.91 |
10:37 ET | 1602 | 10.93 |
10:39 ET | 685 | 10.95 |
10:42 ET | 1400 | 10.96 |
10:44 ET | 700 | 10.96 |
10:46 ET | 5982 | 10.97 |
10:48 ET | 2766 | 10.94 |
10:50 ET | 300 | 10.94 |
10:51 ET | 4095 | 10.9176 |
10:53 ET | 1508 | 10.92 |
10:55 ET | 3500 | 10.92 |
10:57 ET | 3719 | 10.955 |
11:00 ET | 4836 | 11.02 |
11:02 ET | 10491 | 11.14 |
11:04 ET | 1316 | 11.19 |
11:06 ET | 2300 | 11.1602 |
11:08 ET | 2036 | 11.21 |
11:09 ET | 1674 | 11.23 |
11:11 ET | 9975 | 11.2422 |
11:13 ET | 1810 | 11.245 |
11:15 ET | 6077 | 11.24 |
11:18 ET | 2600 | 11.12 |
11:20 ET | 1800 | 11.11 |
11:22 ET | 6954 | 11.15 |
11:24 ET | 2056 | 11.12 |
11:26 ET | 1356 | 11.115 |
11:27 ET | 2900 | 11.15 |
11:29 ET | 2314 | 11.14 |
11:31 ET | 1243 | 11.09 |
11:33 ET | 4733 | 11.09 |
11:36 ET | 500 | 11.11 |
11:38 ET | 1323 | 11.09 |
11:40 ET | 5356 | 11.06 |
11:42 ET | 23929 | 10.99 |
11:44 ET | 1700 | 10.99 |
11:45 ET | 200 | 10.99 |
11:47 ET | 2887 | 10.99 |
11:49 ET | 2199 | 10.96 |
11:51 ET | 1264 | 10.94 |
11:54 ET | 2300 | 10.97 |
11:56 ET | 1100 | 10.94 |
11:58 ET | 616 | 10.93 |
12:00 ET | 1000 | 10.93 |
12:02 ET | 1100 | 10.95 |
12:03 ET | 11526 | 10.9299 |
12:05 ET | 4375 | 10.905 |
12:07 ET | 818 | 10.86 |
12:09 ET | 616 | 10.82 |
12:12 ET | 800 | 10.835 |
12:14 ET | 5527 | 10.77 |
12:16 ET | 3944 | 10.82 |
12:18 ET | 1900 | 10.7701 |
12:20 ET | 1299 | 10.765 |
12:21 ET | 1500 | 10.79 |
12:23 ET | 3200 | 10.75 |
12:25 ET | 1500 | 10.75 |
12:27 ET | 700 | 10.76 |
12:30 ET | 800 | 10.74 |
12:32 ET | 958 | 10.71 |
12:34 ET | 300 | 10.71 |
12:36 ET | 1937 | 10.695 |
12:38 ET | 6160 | 10.7001 |
12:39 ET | 600 | 10.72 |
12:41 ET | 300 | 10.71 |
12:43 ET | 1380 | 10.69 |
12:45 ET | 303 | 10.68 |
12:48 ET | 2500 | 10.69 |
12:50 ET | 200 | 10.7 |
12:52 ET | 735 | 10.68 |
12:54 ET | 1745 | 10.67 |
12:56 ET | 1500 | 10.66 |
12:57 ET | 705 | 10.66 |
12:59 ET | 3900 | 10.68 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Vir Biotechnology Inc | 1.4B | -2.7x | --- |
Arcus Biosciences Inc | 1.4B | -5.2x | --- |
Immatics NV | 1.1B | -11.0x | --- |
Prothena Corporation PLC | 1.1B | -6.7x | --- |
Protagonist Therapeutics Inc | 1.7B | 11.9x | --- |
Silence Therapeutics PLC | 979.4M | -19.4x | --- |
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.4B |
---|---|
Revenue (TTM) | $79.6M |
Shares Outstanding | 136.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.49 |
EPS | $-4.01 |
Book Value | $11.80 |
P/E Ratio | -2.7x |
Price/Sales (TTM) | 17.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -780.18% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.